Tuberculosis (TB) is the commonest cause of death by a single infectious agent globally and
ranks amongst the top ten causes of global mortality. The incidence of TB is highest in Low …

Despite the availability of effective treatment regimens for cutaneous tuberculosis,
challenges to disease control result from delayed diagnosis, infection with multidrug …

In drug hypersensitivity, drug provocation testing (DPT), also called drug challenge, is the
gold standard for investigation. In recent years, risk stratification has become an important …

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and
treatment interruption. The aim of these clinical standards is to encourage best practise for …

Cutaneous lichenoid drug eruptions (LDE) are adverse drug reactions (ADR) characterized
by symmetric, erythematous, violaceous papules reminiscent but rarely fully characteristic of …

Objective In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity
reaction under tuberculosis treatment and the management of hypersensitivity. Methods The …

Background: The World Health Organization Global Tuberculosis Report 2021 defines
tuberculosis as the second infectious disease that causes sickness and death after COVID …

Drug reaction with eosinophilia and systemic symptoms (DRESS) and drug-induced liver
injury (DILI) can hamper therapeutic strategy, contribute to multiple drug resistance and …

Background Data about drug hypersensitivity reactions with first-line antituberculosis drugs
and their management is limited. Rapid drug desensitization seems to be an appropriate …

Objective To evaluate drug resıstant tuberculosis patients who developed drug
hypersensitivity to antituberculosis drug. Methods This was a retrospective study. The …